0001213900-22-025228 | 10-Q | XBRL Viewer | Docgo INC

This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.

Print Document View Excel Document

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of accrued liabilities [Abstract]
Medicare advance	$ 290,582	$ 975,415
FICA/Medicare liability	739,629	739,629
Accrued general expenses	5,055,226	3,497,418
Accrued subcontractors	10,500,202	9,564,833
Accrued fuel and maintenance	463,555	450,842
Credit card payable	$ 107,294	$ 58,223

Label

Element

Value

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchase

dcgo_RevenueLoss

85,379

dcgo_TotalRevenues

115,053,431

dcgo_TotalRevenues

47,681,374

dcgo_TotalRevenues

2,838,121

dcgo_TotalRevenues

2,007,482

dcgo_TotalRevenues

117,891,552

dcgo_TotalRevenues

49,688,856

dcgo_TotalRevenues

27,812,510

dcgo_TotalRevenues

19,124,020

dcgo_TotalRevenues

90,079,042

dcgo_TotalRevenues

30,564,836

dcgo_TotalRevenues

117,891,552

dcgo_TotalRevenues

49,688,856

StockCompensation

dcgo_StockCompensation

367,818

StockCompensation

dcgo_StockCompensation

1,055,119

StockCompensation

dcgo_StockCompensation

1,422,937

StockCompensation

dcgo_StockCompensation

195,767

StockCompensation

dcgo_StockCompensation

195,767

StockCompensation

dcgo_StockCompensation

391,534

dcgo_TotalFairValue

7,381,800

dcgo_TotalFairValue

7,383,000

dcgo_TotalFairValue

1,386,026

dcgo_DueToSeller

160,250

DepreciationExpenses

dcgo_DepreciationExpenses

855,781

DepreciationExpenses

dcgo_DepreciationExpenses

$ 646,812

MedicareAcceleratedPaymentsDescription

dcgo_MedicareAcceleratedPaymentsDescription

At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid.

TotalCurrentAssets

dcgo_TotalCurrentAssets

$ 509,769

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

34.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

22.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

17.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

26.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

13.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

10.00%

ConcentrationRiskPercentage

dcgo_ConcentrationRiskPercentage

3.00%

dcgo_AcquiredAmount

$ 655,876

PurchasePricePerShare

dcgo_PurchasePricePerShare

$ 0.01

PurchasePricePerShare

dcgo_PurchasePricePerShare

0.01

PurchasePricePerShare

dcgo_PurchasePricePerShare

$ 3,000

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

$ 333,025

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

333,025

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

2,063,000

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

2,063,000

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

NoncontrollingInterestContribution

dcgo_NoncontrollingInterestContribution

AccountsReceivableOutstanding

dcgo_AccountsReceivableOutstanding

50.00%

NationalProvidersAssociationLLCDescription

dcgo_NationalProvidersAssociationLLCDescription

The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the condensed consolidated balance sheets. Changes in value of RND are recorded in “Loss from equity method investment” on the Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions.On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC (“NPA”) for $30,000. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the condensed consolidated balance sheets. Changes in value of NPA are recorded in “Loss from equity method investment” on the Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions. Effective December 21, 2021, three members withdrew from NPA resulting in the remaining two members obtaining the remaining ownership percentage.

PropertyPlantAndEquipmentsUsefulLife

dcgo_PropertyPlantAndEquipmentsUsefulLife

Indefinite

PropertyPlantAndEquipmentsUsefulLife

dcgo_PropertyPlantAndEquipmentsUsefulLife

Indefinite

WarrantToPurchaseShares

dcgo_WarrantToPurchaseShares

1,367

WarrantToPurchaseShares

dcgo_WarrantToPurchaseShares

2,461

WarrantToPurchaseShares

dcgo_WarrantToPurchaseShares

667

IssuanceOfFairValue

dcgo_IssuanceOfFairValue

$ 5,400

IssuanceOfFairValue

dcgo_IssuanceOfFairValue

3,000

IssuanceOfFairValue

dcgo_IssuanceOfFairValue

$ 2,078

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

$ 195

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

374,149

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

374,344

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

StockIssuedDuringPeriodValueExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodValueExerciseOfStockOptions

NumberOfCustomers

dcgo_NumberOfCustomers

1

NumberOfCustomers

dcgo_NumberOfCustomers

1

PercentageNonCumulativeDividends

dcgo_PercentageNonCumulativeDividends

8.00%

ClassOfWarrantOrRightExercised

dcgo_ClassOfWarrantOrRightExercised

1,587,700

ClassOfWarrantOrRightExercised

dcgo_ClassOfWarrantOrRightExercised

229,807

StockIssuedDuringPeriodSharesExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodSharesExerciseOfStockOptions

195,152

StockIssuedDuringPeriodSharesExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodSharesExerciseOfStockOptions

StockIssuedDuringPeriodSharesExerciseOfStockOptions

dcgo_StockIssuedDuringPeriodSharesExerciseOfStockOptions

CommonStockRate

dcgo_CommonStockRate

1,000

PaidPreferredStockValue

dcgo_PaidPreferredStockValue

3,000

PercentageOfInterestInRNDHealthServices

dcgo_PercentageOfInterestInRNDHealthServices

50.00%

FinancingLeasePayments

dcgo_FinancingLeasePayments

$ 622,575

MedicareAcceleratedPayments

dcgo_MedicareAcceleratedPayments

290,582

MedicareAcceleratedPayments

dcgo_MedicareAcceleratedPayments

975,415

IncomeTaxExpensebenefit

dcgo_IncomeTaxExpensebenefit

440,179

IncomeTaxExpensebenefit

dcgo_IncomeTaxExpensebenefit

$ 10,029

TotalAuthorizedCommonSharesIncreased

dcgo_TotalAuthorizedCommonSharesIncreased

154,503

IncomeLossFromEquityMethodsInvestments

dcgo_IncomeLossFromEquityMethodsInvestments

$ (83,341)

IncomeLossFromEquityMethodsInvestments

dcgo_IncomeLossFromEquityMethodsInvestments

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestExercisableNumber

dcgo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestExercisableNumber

2,700,000

MajorCustomerPolicyPolicyTextBlock

dcgo_MajorCustomerPolicyPolicyTextBlock

Major Customers

The Company has one customer that accounted for approximately 34% of sales and 22% of net accounts receivable, and another customer that accounted for 19% of sales and 17% of net accounts receivable for the period ended March 31, 2022. As of the period ended March 31, 2021, one customer accounted for approximately 26% of sales and 13% of net accounts receivable, and another customer that accounted for 10% of sales and 3% of net accounts receivable. The Company expects to maintain its relationships with these customers.

StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

146,853

StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

dcgo_StockIssuedDuringPeriodValueUKLtdSharesPurchaseShares

UnderwritersFees

dcgo_UnderwritersFees

$ 114,600,000

AccumulatedDepreciation

dcgo_AccumulatedDepreciation

7,951,023

AccumulatedDepreciation

dcgo_AccumulatedDepreciation

$ 7,095,242

MedicarePaymentPercentage

dcgo_MedicarePaymentPercentage

25.00%

EmergingGrowthCompanyPolicyTextBlock

dcgo_EmergingGrowthCompanyPolicyTextBlock

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

WarrantLiabilitiesPolicyTextBlock

dcgo_WarrantLiabilitiesPolicyTextBlock

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates its financial instruments to determine if such instruments contain features that qualify as embedded derivatives.

dcgo_TotalAssets

$ 215,635,997

dcgo_TotalAssets

109,560,307

dcgo_TotalAssets

325,196,304

dcgo_TotalAssets

87,627,899

dcgo_TotalAssets

18,975,128

dcgo_TotalAssets

106,603,027

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

StockIssuedEffectOfReverseAcquisition

dcgo_StockIssuedEffectOfReverseAcquisition

RestrictedCashAndInsuranceReservesPolicyTextBlock

dcgo_RestrictedCashAndInsuranceReservesPolicyTextBlock

Restricted Cash and Insurance Reserves

Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Condensed Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for its line of credit, transportation equipment leases and a standby letter of credit as required by its insurance carrier (see Notes 8 and 13).

The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits.

ARM Insurance, Inc. a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.

The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in “Restricted cash” in the accompanying Condensed Consolidated Balance Sheets.

StockbasedCompensationExpense

dcgo_StockbasedCompensationExpense

$ 82,304

dcgo_CostOfRevenues

77,987,573

dcgo_CostOfRevenues

35,860,742

TotalGrantdateFairValue

dcgo_TotalGrantdateFairValue

$ 1,049,999

WeightedaveragePeriod

dcgo_WeightedaveragePeriod

3 years 4 months 24 days

CashHeldTrustAccount

dcgo_CashHeldTrustAccount

$ 43,400,000

SoftwareDevelopmentCostsPolicyTextBlock

dcgo_SoftwareDevelopmentCostsPolicyTextBlock

Software Development Costs

Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software. Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life.

Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.

UnrecognizedCompensationCost

dcgo_UnrecognizedCompensationCost

$ 1,467,949

CashPaidForInterest

dcgo_CashPaidForInterest

68,222

CashPaidForInterest

dcgo_CashPaidForInterest

$ 2,365

StockIssuedEffectOfReverseAcquisitioninShares

dcgo_StockIssuedEffectOfReverseAcquisitioninShares

18,099,548

StockIssuedEffectOfReverseAcquisitioninShares

dcgo_StockIssuedEffectOfReverseAcquisitioninShares

22,900,719

StockIssuedEffectOfReverseAcquisitioninShares

dcgo_StockIssuedEffectOfReverseAcquisitioninShares

35,488,938

RevolvingAdvancesDescription

dcgo_RevolvingAdvancesDescription

Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (3.50% as of March 31, 2022), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days elapsed (“Contract Rate”).

RevolvingAdvancesDescription

dcgo_RevolvingAdvancesDescription

Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (3.25% at December 31, 2021), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period.

CashPaidForInterestOnFinanceLeaseLiabilities

dcgo_CashPaidForInterestOnFinanceLeaseLiabilities

$ 153,327

CashPaidForInterestOnFinanceLeaseLiabilities

dcgo_CashPaidForInterestOnFinanceLeaseLiabilities

121,356

LeaseLiabilityNetOfNonCurrentPortion

dcgo_LeaseLiabilityNetOfNonCurrentPortion

2,788,103

LeaseLiabilityNetOfNonCurrentPortion

dcgo_LeaseLiabilityNetOfNonCurrentPortion

$ 2,980,946

LineOfCreditPolicyPolicyTextBlock

dcgo_LineOfCreditPolicyPolicyTextBlock

Line of Credit

The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense.

RelatedPartyTransactionPolicyTextBlock

dcgo_RelatedPartyTransactionPolicyTextBlock

Related Party Transactions

The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, and members of immediate families of principal owners or management, other parties with which the Company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Related party transactions are recorded within operating expenses in the Company’s Condensed Consolidated Statement of Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the periods ended March 31, 2022 and 2021, refer to Note 15.

ScheduleOfEstimatedUsefulLivesTableTextBlock

dcgo_ScheduleOfEstimatedUsefulLivesTableTextBlock

Asset Category		Estimated Useful Life
Buildings		39 years
Office equipment and furniture		3 years
Vehicles		5-8 years
Medical equipment		5 years
Leasehold improvements		Shorter of useful life of asset or lease term

ReclassificationsPolicyTextBlock

dcgo_ReclassificationsPolicyTextBlock

Reclassifications

Certain reclassifications of amounts previously reported have been made to the accompanying Condensed Consolidated Financial Statements to maintain consistency between periods presented. The reclassifications had no impact on previously reported net income or retained earnings.

TotalStockholdersDeficit

dcgo_TotalStockholdersDeficit

$ 510,485

StockOptionAwardsGranted

dcgo_StockOptionAwardsGranted

22,868,377

StockOptionAwardsGranted

dcgo_StockOptionAwardsGranted

20,792,804

TotalLiabilities

dcgo_TotalLiabilities

1,020,254

ReconciliationOfCash

dcgo_ReconciliationOfCash

188,353,909

ReconciliationOfCash

dcgo_ReconciliationOfCash

28,134,967

AcquisitionOfLeasedAssets

dcgo_AcquisitionOfLeasedAssets

$ 759

ScheduleOfActivityUnderRSUsbTableTextBlock

dcgo_ScheduleOfActivityUnderRSUsbTableTextBlock

		RSUs				Weighted- Average Grant Date Fair Value Per RSU
Balance as of, December 31, 2021			50,192			$	9.97
Granted			146,853				7.15
Vested and issued			(8,258	)			9.97
Forfeited			-				-
Balance as of, March 31, 2022			188,787				7.78
Vested and unissued at March 31, 2022			-				-
Non-vested at March 31, 2022			188,787				7.78

ReconcillationOfRestrictedCash

dcgo_ReconcillationOfRestrictedCash

$ 10,370,398

ReconcillationOfRestrictedCash

dcgo_ReconcillationOfRestrictedCash

3,119,484

StockIssuedDuringPeriodValueEquityCost

dcgo_StockIssuedDuringPeriodValueEquityCost

(19,570)

StockIssuedDuringPeriodValueEquityCost

dcgo_StockIssuedDuringPeriodValueEquityCost

(19,570)

TotalCashAndRestrictedCashShownInStatementOfCashFlows

dcgo_TotalCashAndRestrictedCashShownInStatementOfCashFlows

198,724,307

TotalCashAndRestrictedCashShownInStatementOfCashFlows

dcgo_TotalCashAndRestrictedCashShownInStatementOfCashFlows

31,254,451

InstallmentAmount

dcgo_InstallmentAmount

60,499

dcgo_NetProceeds

$ 158,000,000

Stock Based Compensation (Details) - Schedule of company’s stock option activity	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Schedule of company’s stock option activity [Abstract]
Weighted Average Remaining Contractual Life in Years, Beginning	8 years 9 months 7 days
Weighted Average Remaining Contractual Life in Years, Granted/ Vested during the year	9 years 10 months 20 days
Weighted Average Remaining Contractual Life in Years, Exercised during the year	6 years 9 months 7 days
Aggregate Intrinsic Value, Exercised during the year
Options Shares, Cancelled during the year	(47,195)
Weighted Average Exercise Price, Cancelled during the year (in Dollars per share) \| $ / shares	$ 6.78
Weighted Average Remaining Contractual Life in Years, Cancelled during the year	8 years 9 months 29 days
Weighted Average Remaining Contractual Life in Years, Ending	8 years 7 months 28 days
Weighted Average Remaining Contractual Life in Years, Options vested and exercisable	7 years 18 days

Stock Based Compensation (Details) - Schedule of activity under RSUs	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Schedule of activity under RSUs [Abstract]
RSUs, Balance \| shares	50,192
Weighted- Average Grant Date Fair Value Per RSU, Balance	$ 9.97
RSUs, Granted \| shares	146,853
Weighted- Average Grant Date Fair Value Per RSU, Granted	$ 7.15
RSUs, Vested and issued \| shares	(8,258)
Weighted- Average Grant Date Fair Value Per RSU, Vested and issued	$ 9.97
RSUs, Forfeited \| shares
Weighted- Average Grant Date Fair Value Per RSU, Forfeited
RSUs, Balance \| shares	188,787
Weighted- Average Grant Date Fair Value Per RSU, Balance	$ 7.78
RSUs, Vested and unissued \| shares
Weighted- Average Grant Date Fair Value Per RSU, Vested and unissued
Weighted- Average Grant Date Fair Value Per RSU, Non-vested	$ 7.78